Publication | Open Access

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

Breast OncologyOncologyMedicinePathologyLine TherapyLiposomal DoxorubicinBreast CancerTumor TargetingCancer TreatmentPharmacologyRadiation Oncology